Patterns of hospice use in patients dying from hematologic malignancies

Journal of Palliative Medicine

Volumn 17, Issue 2, 2014, Pages 195-199

  Sexauer, Amy ^a   Cheng, M Jennifer ^a   Knight, Louise ^b   Riley, Anthony W ^c   King, Lauren ^a   Smith, Thomas J ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Gilchrist Hospice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; FEMALE; HEMATOLOGIC NEOPLASMS; HOSPICE; HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TERMINAL CARE; UNITED STATES; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMATOLOGIC NEOPLASMS; HOSPICES; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TERMINAL CARE; UNITED STATES;

EID: 84894205331     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2013.0250     Document Type: Article

References (43)

1. Smith TJ, Temin S, Alesi E, et al.: American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care. J Clinical Oncol 2012;30:880-887.
2. Smith TJ, Schnipper LJ: The American Society of Clinical Oncology Program to Improve End-of-Life Care. J Palliat Med 1998;1:221.
3. Peppercorn JM, Smith TJ, Helft PR, et al.: American Society of Clinical Oncology statement: Toward individualized care for patients with advanced cancer. J Clin Oncol 2011;29:755-760.
4. Nelson C, Chand P, Soratais J, Oloimooja J, Rembert G: Inpatient palliative care consults and the probability of hospital readmission. Perm J 2011;15:48-51.
5. Equidanos S, Vesper E, Lorenz K: 30-day readmissions among seriously ill older adults. J Palliat Med 2012;15:1356-1361.
6. Fitch K, Pyenson P: Cancer patients receiving chemotherapy: Opportunities for better management. New York: Milliman, 2010.
7. Manitta VJ, Philip JAM, Cole-Sinclair MF: Palliative care and the hemato-oncological patient: Can we live together? S review of the literature. J Palliat Med 2010;13:1021-1025.
8. Chow K, Coyle N: Providing palliative care to family caregivers throughout the bone marrow transplantation trajectory: Research and practice: Partners in care. J Hosp Pall Nursing 2011;13:7-13.
9. Epstein AS, Goldberg GR, Meier DE: Palliative care and hematologic oncology: The promise of collaboration. Blood Rev 2012;26:233-239.
10. Grundy M, Ghazi F: Research priorities in haemato-oncology nursing: Results of a literature review and a Delphi study. Eur J Oncol Nurs 2009;13:235-249.
11. Lee SJ, Fairclough D: Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA 2001;285:1034-1038.
12. Chantal JNM, Neil MJB, Sam A: What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses. BMJ 1997;315:1202-1203.
13. Mercadante S, Ferrera P, Villari P, David F, Giarratano A, Riina S: Effects of red blood cell transfusion on anemiarelated symptoms in patients with cancer. J Palliat Med 2009;12:60-63.
14. American Cancer Society: ACS Facts and Figures. American Cancer Society, 2010.
15. Ma X, Does M, Raza A, Main ST: Melodysplastic syndromes: Incidence and survival in the United States. Cancer 2007;109:1536-1542.
16. Earle CC, Chapman RH, Baker CS, et al.: Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000;18:3302-3317.
17. Smith TJ, Hillner BE: Bending the cost curve in cancer care. N Engl J Med 2011;364:2060-2065.
18. Riley GF, Lubitz JD: Long-term trends in Medicare payments in the last year of life. Health Serv Res 2010;45:565-576.
19. Gaeta S, Price KH: End-of-life issues in critically ill cancer patients. Crit Care Clin 2010;26:219-227.
20. Kelley AS, Deb P, Du Q, Aldridge Carlson MD, Morrison RS: Hospice enrollment saves money for Medicare and improves care quality across a number of different lengthsof-stay. Health Aff 2013;32:552-561.
21. Christakis NA, Iwashyna TJ: The health impact of health care on families: A matched cohort study of hospice use by decedents and mortality outcomes in surviving, widowed spouses. Soc Sci Med 2003;57:465-475.
22. Morden NE, Chang CH, Jacobson JO, et al.: End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Aff 2012;31:786-796.
23. National Hospice and Palliative Care Organization: NCHPO Facts and Figures: Hospice Care in America. National Hospice and Palliative Care Organization, 2012.
24. Center for Medicare and Medicaid Services: Medicare Hospice Data. www.cms.gov/Medicare/Medicare-Fee-For-Service-Payment/Hospice/ Medicare-Hospice-Data.html. Center for Medicare and Medicaid Services, 2013.
25. Teno JM, Casarett D, Spence C, Connor S: It is "too late" or is it? bereaved family member perceptions of hospice referral when their family member was on hospice for seven days or less. J Pain Symptom Manage 2012;43:732-738.
26. Furman CD, Doukas DJ, Reichel W: Unlocking the closed door: Arguments for open access hospice. Am J Hosp Palliat Care 2010;27:86-90.
27. Freund K, Weckmann MT, Casarett DJ, Swanson K, Brooks MK, Broderick A: Hospice eligibility in patients who died in a tertiary care center. J Hosp Med 2012;7:218-223.
28. Weckmann MT, Freund K, Bay C, Broderick A: Medical manuscripts impact of hospice enrollment on cost and length of stay of a terminal admission. Am J Hosp Palliat Care 2012;1-3.
29. Wittenberg-Lyles E, Diller A, Sanchez-Reilly S, Regehr K: Does exposure to palliative care prior to hospice make a difference for caregivers? J Palliat Med 2009;12:6.
30. Morrison RS, Dietrich J, Ladwig S, et al.: Palliative care consultation teams cut hospital costs for Medicaid beneficiaries. Health Aff 2011;30:454-463.
31. Meyer H: Changing the conversation in California about care near the end of life. Health Aff 2011;30:390-393.
32. Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR: Haematological malignancy: Are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med 2011;25:630-641.
33. Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J: Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 2005;22:943-955.
34. Iwashyna TJ, Zhang JX, Christakis NA: Disease-specific patterns of hospice and related healthcare use in an incidence cohort of seriously ill elderly patients. J Palliat Med 2002;5:531-538.
35. Fadul N, Elsayem A, Palmer JL, Tao Z, Braiteh F, Bruera E: Predictors of access to palliative care services among patients who died at a comprehensive cancer center. J Palliat Med 2007;10:1146-1152.
36. Salpeter SR, Malter DS, Luo EJ, Lin AY, Stuart B: Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012;15:175-185.
37. Kumar SK, Lee JH, Lahuerta JJ, et al.: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 2012;26:149-157.
38. Witzig TE, Tang H, Micallef IN, Ansell SM, et al.: Multiinstitutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood 2011;118:4882-4889.
39. Kadia TM, Jabbor E, Kantarjian H: Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 2011;38:682-692.
40. Al-ali HK, Jaekel N, Junghanss C, et al.: Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: A multicenter phase I/II study. Leuk Lymphoma 2012;53:110-117.
41. Garg RJ, Kantarjian H, O'Brien S, Quintás-Cardama A, Faderl S, Estrov Z, Cortes J: The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up. Blood 2009;114:4361-4368.
42. Cortes J, Lipton JH, Rea D, et al.: Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012;120:2573-2580.
43. Wierda WG, Kipps TJ, Stilgenbauer S, et al.: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-1755.